Hydroxyethyl Amine Compounds Modulating Beta-Secretase Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those targeting beta-secretase mediated diseases, face challenges in effectively reducing beta amyloid plaque formation in the brain, which is a key factor in the progression of Alzheimer's and related disorders.
Innovation Solution
Development of a new class of compounds defined by specific chemical formulas (Formulas I and II) that modulate beta secretase activity, thereby regulating the formation of beta amyloid peptide and reducing beta amyloid plaque formation on the brain, for the treatment of Alzheimer's disease and other beta-secretase mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta secretase activity is inhibited to reduce beta amyloid plaque formation, then Alzheimer's disease treatment efficacy is improved, but the complexity of drug development increases
Solution Approach 1:
The patent segments the beta secretase enzyme into distinct binding regions (S1, S2, S3 subsites) and designs compounds that target specific segments of the active site. This segmentation approach allows for modular drug design where different portions of the molecule can be optimized to interact with specific regions of the enzyme, thereby improving treatment efficacy while managing development complexity through focused optimization strategies
Solution Approach 2:
The patent employs systematic parameter changes by modifying chemical substituents at specific positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10) in the compound structure. By varying these parameters and their corresponding chemical groups, the invention optimizes binding affinity and selectivity for beta secretase, improving treatment efficacy while using structured parameter exploration to manage the complexity of drug development
2Adaptability or versatility
If new compound classes are developed to modulate beta secretase activity, then therapeutic options for Alzheimer's disease are expanded, but the time and resources required for drug development increase
Solution Approach 1:
The patent creates a universal compound scaffold (Formula I structure) that can accommodate multiple different substituent patterns while maintaining beta secretase inhibition activity. This multi-functional design allows a single core structure to serve as the basis for multiple therapeutic candidates with potentially different pharmacokinetic profiles and tissue distributions, expanding therapeutic options without requiring entirely new molecular frameworks for each candidate
Solution Approach 2:
The patent performs preliminary structure-activity relationship (SAR) analysis and computational modeling to predict which substituent patterns will yield active compounds. By conducting preliminary virtual screening and docking studies before synthesizing all possible analogs, the invention reduces the time required for drug development by focusing experimental resources on the most promising candidates identified through preliminary computational action
3Manufacturing precision
If specific chemical structures are optimized for beta secretase inhibition, then selectivity and potency are improved, but the difficulty of synthesis and manufacturing increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and stereochemical features at particular positions (such as the hydroxyethyl amine moiety at specific chiral centers) to enhance binding selectivity for beta secretase. These localized structural features are strategically placed to maximize interaction with key residues in the enzyme active site, achieving high selectivity while keeping the overall molecular framework amenable to synthesis through established organic chemistry methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce beta amyloid peptide formation and plaque deposition, providing a therapeutic approach for treating Alzheimer's disease and related disorders by inhibiting beta secretase activity, thereby slowing disease progression.
Implementation Method 1
Beta secretase (BACE, also commonly referred to as memapsin) is thought to first cleave APP to generate two fragments... Inhibition of the BACE enzyme activity is desirable for the treatment of AD... the compounds of the invention are useful for the modulation of beta secretase activity
Data Source
AI summary
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula Iwherein R1a, R1b, R1c, B, W, R3, R4 and R5 are defined herein. In another embodiment, the invention provides compounds of general Formula IIwherein A1, A2, A3, A4, R1a, R1b, R1c, R2, R4, R5, W, X and Z are defined herein.The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.